Dror Ortho-Design, Inc., a development-stage orthodontic device company, reported in its quarterly filing on July 30 that there is substantial doubt about its ability to continue as a going concern. The company has not yet generated material revenues and remains dependent on external financing to fund its operations and repay liabilities.
The company’s condensed consolidated financial statements for the period ended June 30, 2026, show an accumulated deficit and negative working capital. Cash used in operations during the first six months of the year totaled $709,019, leaving a cash balance of only $93,563 as of the quarter’s end. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months from the issuance of the financial statements.
Funding efforts and bridge loans
To sustain operations, Dror Ortho-Design has relied on a series of private placements of zero-interest debentures. During the quarter, the company sold an additional round of debentures, and all outstanding debentures have been extended to a maturity date of October 31, 2026. The company also received additional funds in June that will be included in a subsequent round of debentures expected in the third quarter. The debentures are structured to automatically convert into common stock at the per-share price of any future public offering, should one occur.
The company is also exploring additional fundraising opportunities. In its filing, management acknowledged that if it cannot raise sufficient capital, it may need to delay, reduce, or eliminate certain research and development programs, sell assets, or merge with another entity.
Development pipeline and regulatory path
Dror Ortho-Design is developing an AI-based orthodontic alignment platform that uses a single smart aligner and pulsating air to move teeth, primarily while patients sleep. The company’s predecessor device received FDA 510(k) clearance in 2020, but the updated platform contains new components and will require a new 510(k) clearance before it can be marketed in the United States. The company has not yet filed its 510(k) submission.
Research and development expenses declined significantly during the quarter, falling 53% compared to the same period last year, primarily due to decreased software development activity. The company estimates it will need to spend approximately $1.5 million over the next 18 months on software and hardware development, regulatory approvals, and intellectual property protection.
The company’s stock trades on the OTC Pink Market under the symbol DROR. The financial statements included in the quarterly report do not reflect any adjustments that might result from the outcome of the going concern uncertainty.